Company / Capital Returned to Shareholders
ResMed Capital Returned to Shareholders History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$610.9M
FY2025
5-year range
$226.7M / $610.9M
FY2021-FY2025
Trend
+41.3%
vs FY2024
Sector context
#31 of 103
Health Care
What the data says
At $611M, ResMed's capital returned to shareholders ranks #31 of 103 in the Health Care sector. Capital Returned to Shareholders has increased for 5 consecutive years, from $225M in FY2020 to $611M in FY2025.
Based on SEC 10-K filings.
$611M in FY2025 with a 5-year CAGR of +22.1%.
Improved from $258M to $611M over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- +35.5%
- 5-Year CAGR
- +22.1%
- 10-Year CAGR
- -
Sector benchmark
#31 of 103 in Health CareTop 30% of 103This company $610.9M Sector average $721.8M
▼
-15.4% below sector average
Key checks
Key Insights
- ResMed's capital returned to shareholders has grown for 5 consecutive years.
- 5-year CAGR of +22.1%, indicating consistent growth.
- In FY2025, capital returned to shareholders increased 41.3% year-over-year.
- Ranks #31 out of 103 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- Strong profit margin: 27.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $610.9M | +41.3% |
| FY2024 | $432.3M | +67.4% |
| FY2023 | $258.3M | +5.3% |
| FY2022 | $245.3M | +8.2% |
| FY2021 | $226.7M | +0.7% |
| FY2020 | $225.1M | -4.0% |
| FY2019 | $234.6M | -7.4% |
| FY2018 | $253.3M | +35.9% |
| FY2017 | $186.3M | -31.0% |
| FY2016 | $270.2M | -14.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026